Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes
- VOSO, MARIA TERESA
- BUCCISANO, FRANCESCO
- AMADORI, SERGIO
- Santini, V
- Finelli, C
- Musto, P
- Pogliani, E
- Angelucci, E
- Fioritoni, G
- Alimena, G
- Maurillo, L
- Cortelezzi, A
- Gobbi, M
- Borin, L
- Di Tucci, A
- Zini, G
- Petti, Mc
- Martinelli, G
- Fabiani, E
- Fazi, P
- Vignetti, M
- Piciocchi, A
- Liso, V
- Leone, G.
Publication date
August 2009
DOI Publisher
American Association for Cancer Research (AACR)Abstract
Epigenetic changes play a role and cooperate with genetic alterations in the pathogenesis of myelodysplastic syndromes (MDS). We conducted a phase II multicenter study on the combination of the DNA-methyltransferase inhibitor 5-azacytidine (5-AZA) and the histone deacetylase inhibitor valproic acid (VPA) in patients with higher risk MDS
Add to ORKG